SLC5A1 and diabetes mellitus: Additionally, and in line with the glucose-centric view of diabetes, treatment with adjunctive therapies based on SGLT1/2 inhibitors have been reported to decrease circulating glucose level; yet, at the expenses of increase DKA risk65.